Minor
Suspected
विवरण
Azithromycin is a weak CYP3A4 inhibitor that can modestly raise loratadine plasma levels; the clinical impact is minimal given loratadine's wide therapeutic index and low cardiac risk.
तंत्र
Azithromycin inhibits CYP3A4 to a minor degree, reducing hepatic metabolism of loratadine; azithromycin itself carries a small QT-prolonging potential, creating a theoretical additive cardiac risk.
नैदानिक महत्व
No significant QT changes or adverse events are expected at standard doses in patients without underlying cardiac risk factors.
प्रबंधन
No dose adjustment required; exercise caution in patients with QT prolongation risk factors or electrolyte abnormalities.